GB201202433D0 - Controlled drug release - Google Patents
Controlled drug releaseInfo
- Publication number
- GB201202433D0 GB201202433D0 GBGB1202433.7A GB201202433A GB201202433D0 GB 201202433 D0 GB201202433 D0 GB 201202433D0 GB 201202433 A GB201202433 A GB 201202433A GB 201202433 D0 GB201202433 D0 GB 201202433D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- core
- hydrocortisone
- delayed release
- polymer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (33)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1202433.7A GB201202433D0 (en) | 2012-02-13 | 2012-02-13 | Controlled drug release |
RU2014130866A RU2619869C2 (ru) | 2012-02-13 | 2013-02-12 | Композиция гидрокортизона с контролируемым высвобождением |
GB1302406.2A GB2502402B (en) | 2012-02-13 | 2013-02-12 | Controlled drug release |
KR1020147025024A KR102023559B1 (ko) | 2012-02-13 | 2013-02-12 | 제어형 하이드로코티손 방출 제형 |
NZ627468A NZ627468A (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formulation |
MEP-2020-122A ME03742B (me) | 2012-02-13 | 2013-02-12 | Formulacija oslobađanja kontrolisanom hidrokortizonom |
PT137094991T PT2814469T (pt) | 2012-02-13 | 2013-02-12 | Formulação de hidrocortisona de libertação controlada |
PL13709499T PL2814469T3 (pl) | 2012-02-13 | 2013-02-12 | Postać użytkowa hydrokortyzonu o kontrolowanym uwalnianiu |
ES13709499T ES2792069T3 (es) | 2012-02-13 | 2013-02-12 | Formulación de liberación controlada de hidrocortisona |
HUE13709499A HUE048904T2 (hu) | 2012-02-13 | 2013-02-12 | Szabályozott hatóanyag-leadású hidrokortizon készítmény |
MX2014009716A MX361407B (es) | 2012-02-13 | 2013-02-12 | Formulaciones de liberacion controlada de hidrocortisona. |
IN6808DEN2014 IN2014DN06808A (zh) | 2012-02-13 | 2013-02-12 | |
PCT/GB2013/050311 WO2013121184A1 (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formulation |
BR112014020008-4A BR112014020008B1 (pt) | 2012-02-13 | 2013-02-12 | Composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação |
EP13709499.1A EP2814469B1 (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formulation |
JP2014556141A JP6293678B2 (ja) | 2012-02-13 | 2013-02-12 | ハイドロコーチゾンの制御放出製剤 |
RS20200578A RS60346B1 (sr) | 2012-02-13 | 2013-02-12 | Formulacija oslobađanja kontrolisanim hidrokortizonom |
US14/374,179 US9750704B2 (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formulation |
LTEP13709499.1T LT2814469T (lt) | 2012-02-13 | 2013-02-12 | Hidrokortizono kontroliuojamo atpalaidavimo kompozicija |
CN201910452557.1A CN110141557A (zh) | 2012-02-13 | 2013-02-12 | 氢化可的松控制释放制剂 |
CA2864031A CA2864031C (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formulation |
CN201380008921.6A CN104105481A (zh) | 2012-02-13 | 2013-02-12 | 氢化可的松控制释放制剂 |
NZ715616A NZ715616A (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formation |
SI201331723T SI2814469T1 (sl) | 2012-02-13 | 2013-02-12 | Formulacije hidrokortizona s prirejenim sproščanjem |
AU2013220139A AU2013220139B2 (en) | 2012-02-13 | 2013-02-12 | Hydrocortisone controlled release formulation |
DK13709499.1T DK2814469T3 (da) | 2012-02-13 | 2013-02-12 | Hydrocortisonformulering med controlled release |
IL234061A IL234061B (en) | 2012-02-13 | 2014-08-11 | Controlled release hydrocortisone formulation |
HK15104320.6A HK1203824A1 (zh) | 2012-02-13 | 2015-05-06 | 氫化可的松控制釋放製劑 |
ZA2015/08728A ZA201508728B (en) | 2012-02-13 | 2015-11-30 | Hydrocortisone controlled release formulation |
IL245546A IL245546A0 (en) | 2012-02-13 | 2016-05-09 | Controlled release hydrocortisone formulation |
US15/641,650 US10166194B2 (en) | 2012-02-13 | 2017-07-05 | Hydrocortisone controlled release formulation |
CY20201100418T CY1123202T1 (el) | 2012-02-13 | 2020-05-06 | Σκευασμα υδροκορτιζονης ελεγχομενης απελευθερωσης |
HRP20200780TT HRP20200780T1 (hr) | 2012-02-13 | 2020-05-13 | Formulacija za kontrolirano otpuštanje hidrokortizona |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1202433.7A GB201202433D0 (en) | 2012-02-13 | 2012-02-13 | Controlled drug release |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201202433D0 true GB201202433D0 (en) | 2012-03-28 |
Family
ID=45930017
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1202433.7A Ceased GB201202433D0 (en) | 2012-02-13 | 2012-02-13 | Controlled drug release |
GB1302406.2A Active GB2502402B (en) | 2012-02-13 | 2013-02-12 | Controlled drug release |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1302406.2A Active GB2502402B (en) | 2012-02-13 | 2013-02-12 | Controlled drug release |
Country Status (28)
Country | Link |
---|---|
US (2) | US9750704B2 (zh) |
EP (1) | EP2814469B1 (zh) |
JP (1) | JP6293678B2 (zh) |
KR (1) | KR102023559B1 (zh) |
CN (2) | CN104105481A (zh) |
AU (1) | AU2013220139B2 (zh) |
BR (1) | BR112014020008B1 (zh) |
CA (1) | CA2864031C (zh) |
CY (1) | CY1123202T1 (zh) |
DK (1) | DK2814469T3 (zh) |
ES (1) | ES2792069T3 (zh) |
GB (2) | GB201202433D0 (zh) |
HK (1) | HK1203824A1 (zh) |
HR (1) | HRP20200780T1 (zh) |
HU (1) | HUE048904T2 (zh) |
IL (2) | IL234061B (zh) |
IN (1) | IN2014DN06808A (zh) |
LT (1) | LT2814469T (zh) |
ME (1) | ME03742B (zh) |
MX (1) | MX361407B (zh) |
NZ (2) | NZ715616A (zh) |
PL (1) | PL2814469T3 (zh) |
PT (1) | PT2814469T (zh) |
RS (1) | RS60346B1 (zh) |
RU (1) | RU2619869C2 (zh) |
SI (1) | SI2814469T1 (zh) |
WO (1) | WO2013121184A1 (zh) |
ZA (1) | ZA201508728B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
US20160367755A1 (en) * | 2015-06-01 | 2016-12-22 | Massachusetts Institute Of Technology | System and method for neuroendocrine control |
FR3057775B1 (fr) * | 2016-10-26 | 2018-11-02 | Crossject | Solution pharmaceutique d’hydrocortisone pour dispositif d’injection |
KR101982287B1 (ko) * | 2019-01-04 | 2019-05-24 | (주)청아굿푸드 | 천연 추출물 함유 서방성 제제 및 그 제조방법 |
EP4277607A1 (en) | 2021-01-15 | 2023-11-22 | Galventa AG | Pulsatile release caffeine formulation |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552872A (en) | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
JPS6013711A (ja) * | 1983-06-21 | 1985-01-24 | ザ、プロクタ−、エンド、ギヤンブル、カンパニ− | コルチコステロイドを含有する浸透局所製薬組成物 |
GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
IL139728A (en) * | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
US5686106A (en) | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
AU710109B2 (en) | 1996-01-16 | 1999-09-16 | Ap Pharma, Inc. | Topical delivery of drugs to the lower gastrointestinal tract |
DE19718012C1 (de) | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
US6066339A (en) | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
JP2004507487A (ja) * | 2000-08-29 | 2004-03-11 | メファ・アクチェンゲゼルシャフト | 腸疾患治療薬 |
CN1499960A (zh) * | 2001-03-13 | 2004-05-26 | ����˹��ҩ�﹫˾ | 时间治疗剂型 |
DE20220917U1 (de) * | 2001-08-06 | 2004-08-19 | Euro-Celtique S.A. | Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden |
GB0119848D0 (en) | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
HU231030B1 (hu) | 2001-11-23 | 2019-12-30 | Warner Chilcott Company, Llc | Többszörös bevonattal ellátott gyógyszer dózisforma |
WO2005025577A1 (en) | 2003-09-15 | 2005-03-24 | Altana Pharma Ag | Use of ciclesonide for the treatment of inflammatory bowel diseases |
GB0400031D0 (en) * | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
ES2400446T5 (es) | 2006-08-03 | 2017-03-13 | Horizon Pharma Ag | Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática |
BRPI0719319A2 (pt) | 2006-11-17 | 2014-02-04 | Da Volterra | Liberação colônica usando contas de zn/pectina com um revestimento de eudragit |
CN101677958A (zh) | 2007-03-26 | 2010-03-24 | 帝国制药株式会社 | 用于结肠-特异性递送的口服药物制剂 |
JP2011506607A (ja) * | 2007-12-17 | 2011-03-03 | ザリカス インコーポレイティッド | 免疫炎症性障害の処置のための治療法 |
GB0817120D0 (en) | 2008-09-19 | 2008-10-29 | Diurnal Ltd | Treatment of adrenal insufficiency |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
WO2010113177A2 (en) | 2009-03-31 | 2010-10-07 | Reliance Life Sciences Pvt. Ltd. | Oral insulin delivery systems for controlling diabetes |
WO2010115615A1 (en) * | 2009-04-07 | 2010-10-14 | Duocort Pharma Ab | Improved glucocorticoid therapy |
ES2671036T3 (es) * | 2009-11-16 | 2018-06-04 | Evonik Röhm Gmbh | Un proceso de conversión de un copolímero de (met)acrilato sólido en una forma dispersa por medio de un agente dispersante |
IT1405012B1 (it) * | 2010-08-06 | 2013-12-16 | Sofar Spa | Composizioni di beclometasone dipropionato in microsfere gastroresistenti a rilascio modificato e processo per il loro ottenimento |
GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
-
2012
- 2012-02-13 GB GBGB1202433.7A patent/GB201202433D0/en not_active Ceased
-
2013
- 2013-02-12 NZ NZ715616A patent/NZ715616A/en unknown
- 2013-02-12 SI SI201331723T patent/SI2814469T1/sl unknown
- 2013-02-12 AU AU2013220139A patent/AU2013220139B2/en active Active
- 2013-02-12 PT PT137094991T patent/PT2814469T/pt unknown
- 2013-02-12 NZ NZ627468A patent/NZ627468A/en unknown
- 2013-02-12 RU RU2014130866A patent/RU2619869C2/ru active
- 2013-02-12 ES ES13709499T patent/ES2792069T3/es active Active
- 2013-02-12 HU HUE13709499A patent/HUE048904T2/hu unknown
- 2013-02-12 RS RS20200578A patent/RS60346B1/sr unknown
- 2013-02-12 GB GB1302406.2A patent/GB2502402B/en active Active
- 2013-02-12 CN CN201380008921.6A patent/CN104105481A/zh active Pending
- 2013-02-12 BR BR112014020008-4A patent/BR112014020008B1/pt active IP Right Grant
- 2013-02-12 ME MEP-2020-122A patent/ME03742B/me unknown
- 2013-02-12 JP JP2014556141A patent/JP6293678B2/ja active Active
- 2013-02-12 KR KR1020147025024A patent/KR102023559B1/ko active IP Right Grant
- 2013-02-12 US US14/374,179 patent/US9750704B2/en active Active
- 2013-02-12 IN IN6808DEN2014 patent/IN2014DN06808A/en unknown
- 2013-02-12 PL PL13709499T patent/PL2814469T3/pl unknown
- 2013-02-12 WO PCT/GB2013/050311 patent/WO2013121184A1/en active Application Filing
- 2013-02-12 MX MX2014009716A patent/MX361407B/es active IP Right Grant
- 2013-02-12 CN CN201910452557.1A patent/CN110141557A/zh active Pending
- 2013-02-12 DK DK13709499.1T patent/DK2814469T3/da active
- 2013-02-12 EP EP13709499.1A patent/EP2814469B1/en active Active
- 2013-02-12 CA CA2864031A patent/CA2864031C/en active Active
- 2013-02-12 LT LTEP13709499.1T patent/LT2814469T/lt unknown
-
2014
- 2014-08-11 IL IL234061A patent/IL234061B/en active IP Right Grant
-
2015
- 2015-05-06 HK HK15104320.6A patent/HK1203824A1/zh unknown
- 2015-11-30 ZA ZA2015/08728A patent/ZA201508728B/en unknown
-
2016
- 2016-05-09 IL IL245546A patent/IL245546A0/en unknown
-
2017
- 2017-07-05 US US15/641,650 patent/US10166194B2/en active Active
-
2020
- 2020-05-06 CY CY20201100418T patent/CY1123202T1/el unknown
- 2020-05-13 HR HRP20200780TT patent/HRP20200780T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201302406D0 (en) | Controlled drug release | |
AU2016219653A1 (en) | Crystallization Method and Bioavailability | |
AU2016219654A1 (en) | Crystallization method and bioavailability | |
WO2011077451A3 (en) | Controlled release pharmaceutical composition | |
NZ604646A (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
MX2021016109A (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion. | |
WO2012141978A3 (en) | Formulations with reduced viscosity | |
MX2016007134A (es) | Composiciones farmaceuticas mejoradas de pimobendan. | |
PH12021550603A1 (en) | Compositions and methods of manufacturing protein microparticles | |
NZ718514A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
WO2012001705A3 (en) | Pharmaceutical compositions of (r)-lansoprazole | |
HK1190643A1 (zh) | 用於胃腸外施用的吡咯藥物製劑及其製備方法和治療對吡咯化合物敏感的疾病的使用方法 | |
EP2583969A4 (en) | NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS | |
WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
WO2012161518A3 (ko) | RORα의 활성자로서의 신규한 thiourea 유도체 및 이를 함유하는 약학적 조성물 | |
PH12014502834A1 (en) | Pharmaceutical form for extended release of active substances | |
MX369742B (es) | Formulación de liberación modificada. | |
WO2013017910A8 (en) | Extended release pharmaceutical compositions containing paliperidone | |
WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same | |
HK1141451A1 (en) | Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration | |
NZ631426A (en) | Prasugrel-containing immediate release stable oral pharmaceutical compositions | |
CA2733299A1 (en) | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer | |
WO2012014052A3 (en) | Novel coated extended release pharmaceutical compositions containing paliperidone | |
EP2452678A3 (en) | Pulsatile-release pharmaceutical formulation of dexlansoprazole | |
WO2012019428A8 (zh) | 二苯甲醇类衍生物、其制备方法及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |